Navigation Links
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:10/5/2009

s is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Steve Pakola, CMO
    Tel: +
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW PROVIDENCE, N.J. , Sept. 2, ... a corporate sponsor for MassBio,s 20th Annual Golf Classic, ... MassBioEd Foundation. The event will be held on September ... Plymouth, Massachusetts . The ... Massachusetts through educational programs, workforce development, ...
(Date:9/2/2014)... of a meter in size, are around us every ... health, as in some innovative early cancer treatments, but ... pollution, traffic emissions, cosmetics, sunscreen and electronics. , A ... led by Lan Yang, PhD, the Das Family Career ... their collaborators at Tsinghua University in China have developed ...
(Date:9/2/2014)... Scientists, including University of Oregon chemist Geraldine Richmond, ... of self-assembling, synthetic proteins called peptoid nanosheets that ... accomplishment -- detailed this week in a paper ... Proceedings of the National Academy of Sciences ... of the two-dimensional peptoid nanosheets that can be ...
(Date:9/2/2014)... Persistence Market Research ( http://www.persistencemarketresearch.com/ ... Biopharma and Life Sciences: North America ... technology market for pharmaceutical, biopharma and life sciences is estimated ... to grow at a CAGR of 9.1% from 2014 ... 10,886.0 million in 2019. Browse the full ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5
... May 2 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO) announced ... Officer., Pulmo BioTech Chief Executive Officer Garry McCann said ... the company and that Rajiv,s,experience and financial acumen would be ... of its Phase I Human Trials and then into Phase,II., ...
... 2 eResearchTechnology, Inc.,(eRT), (Nasdaq: ERES ... collection and interpretation services,announced today that Dr. ... Executive Officer, and Richard Baron, the Company,s ... the Deutsche Bank 33rd Annual,Healthcare Conference at ...
... CLARA, Calif., May 2 Finesse Solutions, LLC,Santa ... solutions for,life sciences process applications, announced the release ... pilot and small scale production,applications. The PLSS package ... I/O capability and NEMA 4X enclosures. TruViu(TM) PLSS,consists ...
Cached Biology Technology:Pulmo BioTech Announces Appointment of Chief Financial Officer 2Pulmo BioTech Announces Appointment of Chief Financial Officer 3eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008 2Finesse Solutions Introduces the TruViu(TM) PLSS System 2
(Date:9/2/2014)... spiky legs and their propensity for eating anything, including ... And now research from North Carolina State University finds ... across the eastern United States. , "The good news ... kind of threat to humans," says Dr. Mary Jane ... author of a paper about the research. , The ...
(Date:9/1/2014)... us fat? An increasing amount of research shows an ... a more sedentary lifestyle. Now, a new Cornell University ... Some TV programs might lead people to eat twice ... you,re watching an action movie while snacking your mouth ... lead author on the new article just published in ...
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... by Johns Hopkins sensory biologists studying fruit flies, has revealed ... this same step suffer retinal dystrophies, which manifest as visual ... article, published Jan. 26 in Current Biology paves ... therapies to treat human retinal degeneration. Retinal dystrophies ...
... two languages regularly during pregnancy puts infants on the ... in Psychological Science , a journal of the ... (who spoke both languages regularly during pregnancy) exhibit different ... one language. Psychological scientists Krista Byers-Heinlein and Janet ...
... WI, February 16, 2010-Educators, especially in science and ... desire to learn in their students. Perhaps no ... Marvin Druger. A professor emeritus at Syracuse University, ... Biology. He shared his experiences teaching over 40,000 ...
Cached Biology News:All eyes on retinal degeneration 2Bilingual babies: The roots of bilingualism in newborns 2A mission statement for science educators 2
Candida (IgA) -Ab EIA Sample Size: 5 l...
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
... Whether your protein is in solution or ... using MALDI-TOF/TOF mass spectrometry. Proteins will be digested ... weights (mass) of the peptides are determined by ... top 10 peaks (peptides) from MALDI-TOF will be ...
Biology Products: